Immunovant, Inc.
IMVTNasdaqCIK 1764013HealthcareFiscal year ends Mar 31
All transactions: 12
Non-derivative transactions reported on Forms 4, newest first. Purchases and sales (codes P and S) are open-market trades; the other codes are grants, exercises, withholding and gifts. The reported price is as stated on the form, not a market price.
What these mean: insiders, Form 4, transaction codes, Rule 10b5-1 plans.
| Date | Insider | Transaction | Shares | Reported price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-10-21 | Stout Jay SChief Technology Officer, Officer | Sale | 2,595 | $28.94 | $75.1k | Form 4 |
| 2025-12-12 | Roivant Sciences Ltd.Director, 10% owner | Purchase | 16,666,666 | $21.00 | $350.0m | Form 4 |
| 2025-01-13 | Roivant Sciences Ltd.Director, 10% owner | Purchase | 16,845,010 | $20.00 | $336.9m | Form 4 |
| 2023-10-02 | Roivant Sciences Ltd.Director, 10% owner | Purchase | 1,526,316 | $38.00 | $58.0m | Form 4 |
| 2023-10-02 | Roivant Sciences Ltd.Director, 10% owner | Grant or award | 4,473,684 | $38.00 | $170.0m | Form 4 |
| 2022-10-06 | Roivant Sciences Ltd.10% owner | Purchase | 416,667 | $6.00 | $2.5m | Form 4 |
| 2021-08-02 | Roivant Sciences Ltd.10% owner | Other | 17,021,276 | not reported | not reported | Form 4 |
| 2020-09-17 | Roivant Sciences Ltd.10% owner | Other | 8,773,969 | not reported | not reported | Form 4 |
| 2020-09-04 | Roivant Sciences Ltd.10% owner | Purchase | 380,000 | $33.00 | $12.5m | Form 4 |
| 2020-05-12 | Roivant Sciences Ltd.10% owner | Other | 8,773,969 | not reported | not reported | Form 4 |
| 2020-04-16 | Roivant Sciences Ltd.10% owner | Purchase | 1,034,483 | $14.50 | $15.0m | Form 4 |
| 2019-12-18 | Roivant Sciences Ltd.10% owner | Other | 36,919,967 | $10.00 | $369.2m | Form 4 |
Source: SEC EDGAR, Forms 4. Last ingested by Listed: Oct 30, 2026, 16:48 ET. Listed shows no prices and gives no investment advice.